

Supplementary**Table S1** ICI drug information

ICIs	ICI + RT (n=202), n (%)	ICI alone (n=155), n (%)
Sintilimab	94 (46.5)	73 (47.1)
Toripalimab	24 (11.9)	26 (16.8)
Nivolumab	28 (13.9)	10 (6.5)
Pembrolizumab	24 (11.9)	26 (16.8)
Camrelizumab	27 (13.4)	11 (7.1)
Atezolizumab	3 (1.5)	4 (2.6)
Durvalumab	2 (1.0)	0 (0.0)
Tislelizumab	0 (0.0)	5 (3.2)

ICI, immune checkpoint inhibitor; RT, radiotherapy.